FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1832060645> ?p ?o ?g. }

• W1832060645 endingPage "260" @default.
• W1832060645 startingPage "251" @default.
• W1832060645 abstract "PURPOSE To assess the efficacy of irinotecan (CPT-11) in the treatment of advanced colorectal cancer in both chemotherapy-naive and pretreated patients. PATIENTS AND METHODS Two hundred thirteen patients (aged 18 to 75 years) with metastatic colorectal cancer, World Health Organization (WHO) performance status < or = 2, and life expectancy > or = 3 months were treated with CPT-11 350 mg/m2 every 3 weeks. All 178 patients eligible for efficacy analysis had not received more than one prior fluorouracil (5-FU)-based chemotherapy regimen (adjuvant or palliative) and had adequate hematologic, renal, and hepatic function. RESULTS Primary tumor sites were the colon (71%) and rectum (28%). Sixty-six percent of the patients had > or = two metastatic sites. Ninety-eight percent of the patients had undergone previous surgery, and 77.5% had received prior chemotherapy. Thirty-two of 178 eligible patients achieved on objective response (four complete responses [CRs] and 28 partial responses [PRs]; response rate, 18%; 95% confidence interval, 12.6% to 24.4%), 65 were stable, and 59 progressed. The response rate was 17.7% in the pretreated group and 18.8% in the chemotherapy-naive group. Within the former subgroup, response rates of 16.1% were reported in patients who were progressive on prior 5-FU chemotherapy and 19.1% in patients who were progressive off such treatment. The median duration of objective response (9.1 months) and median time to achievement of a response (9.3 weeks) did not differ between chemotherapy-naive and pretreated patients. The most frequent adverse events were neutropenia, which developed in 80% of the patients, delayed diarrhea (87%), alopecia (88%), fatigue (81%), and nausea/vomiting (77%). All these adverse events were manageable. Severe (WHO grade 3 or 4) neutropenia was only observed in 18% of the cycles, leukopenia in 11%, delayed diarrhea in 11%, and nausea and vomiting in 3%. Development of simultaneous grade 3 or 4 neutropenia and delayed diarrhea during 4% of the cycles was the safety issue of greatest concern. CONCLUSION CPT-11 has definite activity in the treatment of advanced metastatic colorectal cancer both in chemotherapy-naive and in pretreated patients who experienced disease progression on 5-FU, which suggests a lack of cross-resistance between CPT-11 and 5-FU. Diarrhea and neutropenia, the major toxicities of CPT-11, contribute to the risk to develop febrile neutropenic sepsis." @default.
• W1832060645 created "2016-06-24" @default.
• W1832060645 creator A5002652584 @default.
• W1832060645 creator A5006004932 @default.
• W1832060645 creator A5009795240 @default.
• W1832060645 creator A5014414514 @default.
• W1832060645 creator A5014415808 @default.
• W1832060645 creator A5018514406 @default.
• W1832060645 creator A5020353650 @default.
• W1832060645 creator A5020997210 @default.
• W1832060645 creator A5024118579 @default.
• W1832060645 creator A5026512478 @default.
• W1832060645 creator A5030407951 @default.
• W1832060645 creator A5037359039 @default.
• W1832060645 creator A5041520441 @default.
• W1832060645 creator A5049146702 @default.
• W1832060645 creator A5052430948 @default.
• W1832060645 creator A5060740755 @default.
• W1832060645 creator A5068106161 @default.
• W1832060645 creator A5071867163 @default.
• W1832060645 creator A5073216761 @default.
• W1832060645 creator A5077578285 @default.
• W1832060645 creator A5078590777 @default.
• W1832060645 creator A5090993023 @default.
• W1832060645 date "1997-01-01" @default.
• W1832060645 modified "2023-09-28" @default.
• W1832060645 title "Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy." @default.
• W1832060645 cites W1549846058 @default.
• W1832060645 cites W1663737385 @default.
• W1832060645 cites W1774923611 @default.
• W1832060645 cites W1835830368 @default.
• W1832060645 cites W1850727413 @default.
• W1832060645 cites W1952371628 @default.
• W1832060645 cites W1969825132 @default.
• W1832060645 cites W2001096578 @default.
• W1832060645 cites W2011476349 @default.
• W1832060645 cites W2020934472 @default.
• W1832060645 cites W2051318720 @default.
• W1832060645 cites W2057409012 @default.
• W1832060645 cites W2069943574 @default.
• W1832060645 cites W2070237761 @default.
• W1832060645 cites W2095355415 @default.
• W1832060645 cites W2098822886 @default.
• W1832060645 cites W2103489107 @default.
• W1832060645 cites W2110650955 @default.
• W1832060645 cites W2149505692 @default.
• W1832060645 cites W2167805334 @default.
• W1832060645 cites W2177811724 @default.
• W1832060645 cites W2253033732 @default.
• W1832060645 cites W2274948752 @default.
• W1832060645 cites W2415373584 @default.
• W1832060645 cites W2423727003 @default.
• W1832060645 doi "https://doi.org/10.1200/jco.1997.15.1.251" @default.
• W1832060645 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8996150" @default.
• W1832060645 hasPublicationYear "1997" @default.
• W1832060645 type Work @default.
• W1832060645 sameAs 1832060645 @default.
• W1832060645 citedByCount "415" @default.
• W1832060645 countsByYear W18320606452012 @default.
• W1832060645 countsByYear W18320606452013 @default.
• W1832060645 countsByYear W18320606452014 @default.
• W1832060645 countsByYear W18320606452015 @default.
• W1832060645 countsByYear W18320606452016 @default.
• W1832060645 countsByYear W18320606452017 @default.
• W1832060645 countsByYear W18320606452018 @default.
• W1832060645 countsByYear W18320606452019 @default.
• W1832060645 countsByYear W18320606452020 @default.
• W1832060645 countsByYear W18320606452021 @default.
• W1832060645 countsByYear W18320606452022 @default.
• W1832060645 countsByYear W18320606452023 @default.
• W1832060645 crossrefType "journal-article" @default.
• W1832060645 hasAuthorship W1832060645A5002652584 @default.
• W1832060645 hasAuthorship W1832060645A5006004932 @default.
• W1832060645 hasAuthorship W1832060645A5009795240 @default.
• W1832060645 hasAuthorship W1832060645A5014414514 @default.
• W1832060645 hasAuthorship W1832060645A5014415808 @default.
• W1832060645 hasAuthorship W1832060645A5018514406 @default.
• W1832060645 hasAuthorship W1832060645A5020353650 @default.
• W1832060645 hasAuthorship W1832060645A5020997210 @default.
• W1832060645 hasAuthorship W1832060645A5024118579 @default.
• W1832060645 hasAuthorship W1832060645A5026512478 @default.
• W1832060645 hasAuthorship W1832060645A5030407951 @default.
• W1832060645 hasAuthorship W1832060645A5037359039 @default.
• W1832060645 hasAuthorship W1832060645A5041520441 @default.
• W1832060645 hasAuthorship W1832060645A5049146702 @default.
• W1832060645 hasAuthorship W1832060645A5052430948 @default.
• W1832060645 hasAuthorship W1832060645A5060740755 @default.
• W1832060645 hasAuthorship W1832060645A5068106161 @default.
• W1832060645 hasAuthorship W1832060645A5071867163 @default.
• W1832060645 hasAuthorship W1832060645A5073216761 @default.
• W1832060645 hasAuthorship W1832060645A5077578285 @default.
• W1832060645 hasAuthorship W1832060645A5078590777 @default.
• W1832060645 hasAuthorship W1832060645A5090993023 @default.
• W1832060645 hasConcept C121608353 @default.
• W1832060645 hasConcept C126322002 @default.
• W1832060645 hasConcept C141071460 @default.
• W1832060645 hasConcept C143998085 @default.
• W1832060645 hasConcept C197934379 @default.

• next